HK Stock Market Move | CRO concept stocks lead the gains, innovative drug investment and financing and BD going global rebound synchronously, the industry's prosperity is expected to gradually improve.

Concept stocks of CRO lead the gains. As of press time, VIVA BIOTECH (01873) rose by 6.14% to HK$2.42; WUXI BIO (02269) rose by 6.01% to HK$40.54; Hangzhou Tigermed Consulting (03347) rose by 4.65% to HK$56.3; WuXi AppTec (02359) rose by 4.31% to HK$121. On the news front, WuXi AppTec's net profit in 2025 is expected to increase by 103% year-on-year, while Hangzhou Tigermed Consulting is expected to increase by 105-204% year-on-year. Global biopharmaceutical financing data is expected to rebound in 2025, with global and Chinese year-on-year growth rates of 2.7% and 6.4% respectively. Innovative drug research and development is booming, with a projected BD amount of $135.7 billion in 2025, a 143% increase year-on-year. Guotai Junan Securities released a research report stating that as financing and BD repayments rise, pharmaceutical companies are increasing investment in clinical trials, leading to a recovery in the outsourcing demand for clinical CROs, SMOs, and registration services, providing a direct source of funding and project foundation for the industry's recovery. Guotai Junan Securities believes that CXO and upstream research services mainly serve the R&D and production of innovative drugs, and with the booming development of innovative drug research, the performance of these two sectors is expected to remain in good trend.